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Abstract
Purpose Auto-titrating continuous positive airway pressure
(APAP) devices were developed to improve treatment efficacy
and compliance in patients with obstructive sleep apnoea
syndrome (OSAS). Since there are insufficient data on the
optimal pressure range setting, we aimed to compare the ad-
herence, efficacy and tolerability of treatment with high-span
versus low-span APAP.
Methods Seventy-six newly diagnosed OSAS patients fulfill-
ing the treatment criteria were randomised to receive high-
span (HS, range 4–15cmH2O, n=38) or low-span (LS, range
8–12cmH2O, n=38) APAP. Patients were assessed at 1 and
3 months.
Results Median Epworth sleepiness scale (ESS) was 13 (IQR,
6–16) and median apnoea-hypopnoea index (AHI) was 35.9
(IQR, 27.6–56.3). There were no significant differences in
baseline demographic and clinical characteristics between
groups. Overall, no significant differences were found at the
first month assessment. After 3 months of therapy, we found
again no differences in residual AHI or ESS. However, the
group HS proved less adherent than group LS, respectively,
with median 87 % (IQR, 60.5–97.5) versus 94 % (IQR, 80.0–
98.3) of the nights using ≥4 h (P=0.014) and mean (±SD)
usage 5.7±1.6 versus 6.4±1.2 h/night (P=0.049). The group
HS reported more frequently nasal congestion, excessive
oronasal dryness and nocturnal awakenings of at least moder-
ate intensity, the latter with statistical significance (P=0.005).
Conclusions Both pressure ranges appear to be equally effec-
tive to correct AHI and to improve symptoms. Though, pa-
tients with high-span APAP were less compliant to treatment,
raising issues about the tolerability of wide pressure range
settings of these devices.
Keywords Obstructive sleep apnoea . Auto-titrating positive
airway pressure . Pressure range . Treatment compliance
Introduction
Obstructive sleep apnoea syndrome (OSAS) is a com-
mon and potentially serious disorder affecting nearly
4 % of adult population [1]. The hallmark of this con-
dition is the excessive daytime sleepiness, caused by
sleep fragmentation due to repetitive episodes of partial
or complete upper-airway obstruction [2]. It is frequently as-
sociated with neurocognitive deficits, hypertension, myocar-
dial infarction and stroke [3, 4]. The standard treatment is
nocturnal continuous positive airway pressure (CPAP), which
has been shown to improve quality of life, reduce the risk of
road traffic and occupational accidents, and decrease cardio-
vascular morbidity and mortality [5–8].
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Traditionally, after a patient is diagnosed with OSAS, an
attended polysomnography (PSG) is performed, during which
positive airway pressure is manually titrated throughout the
recording period to determine the minimal pressure that main-
tains the upper airway patency. Auto-titrating positive airway
pressure (APAP) devices were developed to allow for a lower
average pressure over the course of the night, through
continuously adjusting the applied pressure to the opti-
mal level, in that way improving the patient comfort
and compliance [9–12]. The rationale for this treatment
modality was based on the observations that the pressure re-
quired to eliminate obstructive respiratory events varies over a
night depending on several factors, like alcohol or hypnotic
agent use, body position, nasal obstruction and sleep state
[13–15]. Additionally, APAP devices seem to be more cost-
effective, since there is no need for PSG to titrate pressures
and, despite scarce data on objective clinical outcomes, its ef-
fectiveness in reducing the apnoea-hypopnoea index (AHI) and
symptoms appears to be similar to that of fixed-pressure CPAP
therapy [16, 17]. However, the American Academy of Sleep
Medicine does not recommend APAP titration or treatment in
patients with congestive heart failure, significant lung disease,
obesity hypoventilation syndrome, non-snoring patients and in
patients with associated central sleep apnoeas [18].
At present time, there is insufficient evidence regarding the
optimal APAP pressure range. Most APAP devices have de-
fault settings ranging from 4 to 20 cmH2O, values thought to
be tolerable and effective for the majority of patients.
However, studies that compare different pressure ranges are
still lacking and it is not clear whether rapid pressure augmen-
tations induce sleep fragmentation.
The present study was designed to compare the impact of
high-span versus low-span APAP pressures on tolerability,




Cases were recruited from the patient population attending the
Respiratory Sleep Disorders Unit at Centro Hospitalar de São
João (Porto, Portugal). Patients were eligible to participate if
they had a confirmed diagnosis of moderate to severe OSAS
(AHI >15 events/h), met the criteria for APAP treatment and
had not been on positive airway pressure (PAP) therapy pre-
viously. Exclusion criteria were as follows: hypercapnia (all
patients with pulse oxygen saturation lower than 94% or body
mass index >30 kg/m2 had an arterial blood gas analysis),
forced expiratory volume in 1 s/forced vital capacity
(FEV1/FVC) ratio <0.7, or FEV1 <70 % predicted, and if
>50 % of the events were central apnoeas. We also excluded
patients with malignant disease and psychiatric disorder or
cognitive disability.
The diagnosis of OSAS was based on an overnight sleep
study by home portable cardiorespiratory polygraph
(Embletta™ Gold Portable Testing Device, Broomfield, USA),
which included monitoring of heart rate, nasal airflow, chest
wall and abdominal excursion, and oxygen saturation. All sleep
studies were manually scored by and experienced sleep techni-
cian and apnoea and hypopnoea were defined according to the
criteria of the American Academy of Sleep Medicine [19]. We
only considered the cases with an adequate record of poly-
graphic sleep study >80 % of the night and/or >6 h.
Criteria for APAP therapy were as follows: AHI≥30 events
per hour; AHI≥15 events per hour with associated symptoms,
that included unintentional sleep episodes while awake, day-
time sleepiness, unrefreshing sleep, fatigue, insomnia, gasping
or choking and loud snoring, or associatedwith cardiovascular
comorbidities [20].
All patients recruited provided written informed consent.
The study protocol was approved by our institution’s Ethics
Committee (approval number 284-12).
Study design
All patients were examined by a pulmonologist with expertise
in sleep medicine. After establishing the diagnosis and the
inclusion criteria, patients were randomised into two different
treatment arms in a 1:1 ratio, according to a random computer-
generated single block allocation sequence: group HS—high-
span APAP, with pressure range from 4 to 15 cmH2O; and
group LS—low-span APAP, with pressure range from 8 to
12 cmH2O (Fig. 1).
Fig. 1 Study design: patients were enrolled to high-span APAP (4–
15 cmH2O, group HS) or low-span APAP (8–12 cmH2O, group LS)
treatment; drop-outs were cases that lost follow-up or had no
compliance data available; patients that had changes in pressure settings
or that switched to bi-level PAP were also excluded from the analysis
184 Sleep Breath (2016) 20:183–190
At enrollment, we collected demographic data, information
on smoking habits and medical background. Subjective sleep-
iness was measured using the Epworth sleepiness scale (ESS)
[21]. Height, weight, neck circumference, arterial blood pres-
sure, cardiac rate and oxygen saturation were measured, and
simple spirometry was performed.
The APAP adherence data were collected at two different
follow-up visits. The patients were firstly referred to a struc-
tured group education session at the sleep clinic in the
pulmonology department approximately 1 month after initiat-
ing the APAP treatment. They were previously advised to
bring their APAP device and interface. The education session
was conducted by a pulmonologist, a psychologist, and a re-
spiratory physiotherapist, as previously described [22]. Each
patient’s adherence reports were analysed after downloading
usage data stored in the device. Under supervision of a respi-
ratory physiotherapist, they were invited to put their interface
on. The adequacy of the model and size of each patient’s mask
were assessed and, whenever necessary, the interface or the
ventilator mode was changed.
The patients were again evaluated at the third month of
APAP treatment in a follow-up group session conducted by
a respiratory physiotherapist. The adherence reports were
reassessed and treatment adjustments took place as needed.
The subjects were asked to complete the items of the ESS,
to determine the degree of daytime sleepiness, and also the
“treatment-related symptoms” domain (domain E) of Sleep
Apnoea Quality of Life Index (SAQLI) questionnaire. This
is an OSAS-specific questionnaire, which was already validat-
ed in Portuguese patients [23]. Patients selected the top five
treatment side effects they experienced (from a list of 26).
Each item was subjectively graded on a seven-point Likert
scale, ranging from 1 (maximal impairment) to 7 (no impair-
ment). Response values were reversed (7 to 0, 6 to 1, 5 to 2, 4
to 3, 3 to 4, 2 to 5, and 1 to 6), and the mean score was
obtained by summing the scores for the five symptoms and
dividing by five (even when the patient selected fewer than
five symptoms).
APAP devices
The APAP device used in this study was S9 AutoSet™
(ResMed, North Ryde, Australia) that automatically delivers
the combination of APAP with Easy-Breathe™ Expiratory
Pressure Relief (EPR) to prevent the collapse of the upper
airway during sleep. Patients were prescribed with nose or
face masks, as appropriated for the facial structure of each
individual, patient comfort and nasal or oral breathing pre-
dominance. Heated humidifiers were not prescribed to any
patient at the beginning of the study. When necessary (com-
plaints of oronasal mucosal dryness), heated humidifiers were
added. All APAP devices carried a monitoring chip for adher-
ence data collection and storage.
Adherence data
After 1 and 3 months of APAP therapy, usage data were
downloaded by sleep technicians during a hospital visit, be-
fore the group education and follow-up session that patients
routinely undergo in our centre, as described above.
Adherence data, air leakage, air pressure delivered and resid-
ual AHI were recorded.
Adherence was analysed as a continuous and as a
dichotomous variable. When analysed as a continuous
variable, we recorded the percentage of days the
APAP was used, the percentage of days with APAP
usage >4 h/night and the mean effective use per effec-
tive day, defined as the cumulative time of effective use
divided by the number of days APAP was actually used.
When analysed as a dichotomous variable, we compared
adherent versus non-adherent. Patients were defined as
being adherent if they used APAP at least 4 h per night for
at least 70 % of days [22, 24].
Statistical analysis
The Kolmogorov–Smirnov test was used to determine the
normality of distribution of all continuous variables, and
Levene’s test was used to assess the equality of variance.
Differences between means were analysed using t tests for
normally distributed variables and Mann–Whitney U tests
for non-normally distributed variables. The chi-squared test
was used to compare frequencies and proportions between
groups. All statistical analyses were performed using SPSS®
software v. 22. A P value <0.05 was considered statistically
significant.
The expected difference in the primary outcome variable
(compliance) which might be clinically important and the
pooled standard deviation were specified on the basis of the
previous published studies [25]. The required sample size to
detect a difference of 1.0 h with 80 % power at the 5 % sig-
nificance level, based on a pooled standard deviation of 1.7 h,
was 38 subjects in each group.
Results
We recruited 92 patients according to the selection criteria and
assigned 46 cases to each treatment arm. As shown in Fig. 1,
three patients in group HS (4–15 cmH2O) and two in group
LS (8–12 cmH2O) dropped out from the study (lost to
follow-up or without compliance data available), and an
additional five and six cases of each group, respectively,
were withdrawn because of changing in treatment condi-
tions (changes in pressure settings or switch to bi-level PAP).
The analysis was performed on the remaining 76 patients who
completed the trial.
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Table 1 shows the demographic and clinical characteristics
of the patient sample. Patients were as expected for a group
with moderate-to-severe OSAS, being predominantly male,
middle-aged and obese. Baseline features did not differ be-
tween groups. There was no significant weight change during
follow-up.
The adherence was high among all patients, with overall
APAP usage in 92.8±16.5 % (mean±SD) of the days at
1 month and 93.1±15.2 % at 3 months of follow-up. At
1 month, the percentage of nights with APAP usage for at least
4 h and the mean hours of use per night were similar between
groups (Fig. 2). However, at 3 months of follow-up, only
66.7 % patients in the group HS were using APAP ≥4 h for
at least 70 % of nights, compared with 88.9 % of pa-
tients of group LS (P=0.025). In the former group, par-
ticipants used APAP ≥4 h in 87 % (IQR, 60.5–97.5) of
the nights, while in the latter participants used in 94 %
(IQR, 80.0–98.3), as shown in Fig. 2 and Table 2 (P=0.014).
In fact, patients at group LS used APAP on average more
42 min per night (6.4±1.2 h/night or mean 6 h, 24 min), than
patients at group HS (5.7±1.6 h/night or mean 5 h, 42 min,
P=0.049). Air leakage did not differ significantly between
groups at both 1 and 3 months of treatment. As already men-
tioned, heated humidifiers were not prescribed at the begin-
ning of the study. During follow-up, three (7.9%) in group HS
and three (7.9 %) in group LS started humidification due to
complaints of oronasal mucosal dryness.
When assessing APAP therapy effectiveness, both groups
reported a significant improvement of subjective daytime
sleepiness measured with the ESS. Similarly, we found no
differences in residual AHI between groups during follow-
up (Fig. 3 and Table 2).
Since there were differences in pressure range and 95th
percentile pressure delivered (Fig. 2), we went to assess the
symptoms related to treatment in SAQLI domain E. Although
patients in group LS reported a lower score, the difference
between treatment arms did not reach statistical significance
(Table 2). Nevertheless, after analysing the six most frequent
side effects of at least moderate intensity (scoring 3 or more in
the reversed 0 to 6 Likert scale), we found that patients treated
with high-span pressure reported more often nasal congestion,
excessive oronasal dryness, discomfort from the mask, facial
marks or rash and repeated nocturnal awakenings, than pa-
tients of low-span group (Fig. 4). However, only the latter
was significantly different (P=0.005).
Discussion
The effectiveness of CPAP depends largely on its regular use.
After three decades of experience since CPAP therapy was
first proposed for treating OSAS [26], and extensive work
published stating its efficiency in the long-term treatment
[27], sleep clinicians are still challenged to find solutions that
improve adherence. By delivering pressure that is continuous-
ly adapting to changes in airflow resistance, APAP is thought
to improve the breathing synchrony with the PAP device and,
therefore, to increase patient comfort and enhance its compli-
ance. The APAP devices are particularly thought to have an
advantage relatively to fixed pressure CPAP in patients requir-
ing high pressures.
The present study aimed to compare the efficacy, adher-
ence and tolerability between low-span and high-span APAP
settings. Both pressure ranges appear to be equally effective to
correct AHI and to improve subjective sleepiness. Though,
patients with high-span APAP were less compliant to treat-
ment at the end of the trial, raising issues about the tolerability
of wide pressure range settings in these devices. We believe
that the difference of 0.7 h/night (a 12.3 % improvement) in
APAP usage observed in the group LS is clinically significant,
Table 1 Baseline demographics and clinical characteristics in group HS (high-span APAP) and group LS (low-span APAP): continuous variables are
presented as mean±SD or median (25th–75th percentile)
Factors associated with mortality All (n=76) HS group (n=38) 4–15 cmH2O LS group (n=38) 8–12 cmH2O P value
Age (years) 56.6±11.2 54.7±12.3 58.6±9.9 0.129
Male gender, n (%) 58 (76.3 %) 28 (73.7 %) 30 (78.9 %) 0.589
BMI (kg/m2) 32.8±5.0 33.0±4.9 32.6±5.2 0.704
Cervical perimeter (cm) 43 (40–46) 43 (39–46) 43 (40–47.9) 0.673
Present or former smoker, n (%) 38 (50 %) 19 (50 %) 19 (50 %) 0.948














Use of sedatives 9 (11.8 %) 4 (10.5 %) 5 (13.2 %) 0.723
ESS 11.2±5.9 11.6±5.8 10.9±6.0 0.644
AHI (/h) 35.9 (27.6–56.3) 39.4 (30.2–61.6) 33.5 (26.8–48.7) 0.158
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Fig. 2 Comparison of APAP use
data between groups HS and LS:
percentage of days using for at
least 4 h,mean hours of APAP use
per night, 95th percentile (P95th)
pressure and air leak, and residual
apnoea-hypopnoea index (AHI)
under treatment. NS not
significant
Table 2 Comparison between groups HS and LS of APAP use data, subjective sleepiness and symptoms related to treatment at the end of the trial:
values are presented as mean±SD or median (25th–75th percentile)
All (n=76) HS group (n=38) 4–15 cmH2O LS group (n=38) 8–12 cmH2O P value
Percentage of days using ≥4 h 87.0 (75.0–98.0) 87.0 (60.5–97.5) 94.0 (80.0–98.3) 0.014a
Mean use (h/night) 6.1±1.4 5.7±1.6 6.4±1.2 0.049a
P95th PAP (cmH2O) 11.9 (10.9–12.9) 13.0 (11.1–14.6) 11.7 (10.9–11.9) 0.001
a
P95th leak (L/min) 13.2 (6.0–27.0) 13.2 (8.7–24.9) 15.0 (5.1–29.4) 0.953
Residual AHI (/h) 1.9 (0.9–3.2) 2.1 (1.0–3.8) 1.7 (0.8–2.6) 0.211
ESS 5.0 (1.7–6.2) 5.0 (2.0–6.0) 4.5 (1.0–7.2) 0.780
SAQLI domain E 1.9±1.4 2.1±1.8 1.8±1.1 0.542
P95th 95th percentile
a Statistically significant results
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since it transposes the target time of 6 hours of use per night.
Several studies have indicated that better outcomes are asso-
ciated with more hours of nightly PAP use [22] and the use for
at least 6 h per night was found to optimise memory perfor-
mance [28]. One should notice that we are comparing two
groups with high adherence levels, which makes the differ-
ence achieved with low-span treatment even more striking.
The overall good adherence reflects the close follow-up that
patients had during the first months of treatment, with com-
pliance reinforcement in group education sessions occurring
at both time points. We have previously published the impact
of a structured education session in enhancing APAP adher-
ence in certain groups of patients [22, 29].
All baseline characteristics were similar between the two
groups, meaning that a good randomisation was achieved. The
only difference at the starting point was the prescription of
treatment, which included a wider range and a higher P95th
PAP in the high-span treatment arm (Fig. 2). We hypothesise
that when PAP provokes nasal congestion, it will, in turn,
drive the device to increase pressure to the available span.
The higher pressure (15 cmH2O in group HS) again worsens
the nasal obstruction and other PAP-related symptoms, in a
vicious cycle. One study showed that greater air leak levels
during APAP therapy were associated to poor adherence [30].
However, contrarily to expected, the disparity of compliance
could not be attributed to increased air leakage in group HS,
since there were no significant differences in this parameter.
In fact, when we assessed the symptoms related to treat-
ment, air leaks were one of the most frequent side effects
reported in both groups, but with comparable severity (Fig. 4).
Conversely, nasal congestion, excessive oronasal dryness and
nocturnal awakenings, which may be directly imputable to
high PAP, were reported more frequently as clinically relevant
(at least of moderate intensity) by patients in high-span group.
Of these, only nocturnal awakenings were significantly more
important in this group, suggesting that the wide pressure
range can induce arousals, which if meaningful, may cause
patients to spend more time awake during the night without
PAP. Of note, there is an overall low incidence of symptoms
related to treatment at the end of the trial, probably due to the
early detection and management of side effects at the first
month follow-up visit after treatment initiation. We believe
that SAQLI domain E score could have a wider and significant
difference between groups if no intervention was employed
during group sessions to minimise complaints.
As mentioned, a higher P95th PAP was observed with the
high-span treatment. However, low-span APAP was equally
effective in a population with the same characteristics, sug-
gesting that most patients can be treated with PAP up to
12 cmH2O. If we check the number of patients removed from
the study during follow-up because they needed to increase
the upper level of PAP or switched to bi-level PAP, we find a
similar proportion in both groups (Fig. 1). In practice, the
optimal PAP level is a trade-off between pressure-related side
effects and effectiveness in preventing upper airway obstruc-
tion during sleep. Our data suggests that patients newly diag-
nosed with OSAS can be initially treated with a trial of low-
span APAP 8 to 12 cmH2O and early reassessed to determine
the effectiveness of treatment with those settings.
To our knowledge, this is the first study comparing the
tolerability, effectiveness and compliance of different APAP
range settings. In the future, a prospective study could be
designed to compare nocturnal PSG, performed during high-
span and low-span APAP use, in order to assess if sleep frag-
mentation is different in the two treatment arms.
Fig. 3 Effectiveness of APAP
therapy
Fig. 4 Frequency of the sixmost prevalent side effects reported as at least
of moderate intensity by patients treated with high-span (group HS) and
low-span (group LS) APAP: nasal congestion, excessive oronasal
dryness, waking up frequently during the night, air leakage from the
mask, discomfort from the mask and marks or rash on the face
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Comment
In the era of increasing long-term auto-titrating positive airway pressure
(APAP) device use for OSA treatment, this study helps sleep physicians
improve adherence without substantive effects on OSA control. This
randomised controlled trial evaluates the effect of high-span (4–15 cm
water) and low-span (8–12 cm water) APAP initial settings on efficacy
and adherence over a 3-month time span. The authors find that there is no
difference in efficacy between the treatment arms and improved adher-
ence with the low-span APAP settings. These findings indicate that there
may be significant differences in long-term adherence based on initial
PAP therapy settings. Long-term studies are needed to further clarify
the issue; however, it may be prudent in selected patients at the
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